Background: The metabolism of pyrimidine deoxynucleo sides and nucleoside reverse transcriptase inhibitors has been studied in growing cells. However, many of these drugs are associated with mitochondrial toxicities observed in nonreplicating tissues, such as in the heart, where their metabolism has not been investigated. Methods: The aims of this study were twofold. The first was to investigate the metabolism of the thymidine analogues 3′azido3′deoxythymidine (AZT) and 2′,3′ didehydrodideoxythymidine (d4T), and the deoxycytidine (dCyd) analogues 2′deoxy3′thiacytidine (3TC) and 2′,3′ dideoxycytidine (ddC) with regard to phosphorylation and breakdown. The second was to investigate their potential effects, singly or in combination with AZT, on metabolism of the naturally occurring deoxynucleosides in the per fused rat heart and in isolated heart mitochondria. Results: The analogue d4T was not metabolized in perfused heart or in isolated mitochondria, and had no effect on either thymidine or dCyd metabolism. The dCyd analogues were both phosphorylated in perfused heart to the triphos phate, but only at the limit of detection and they were not phosphorylated in isolated mitochondria. Neither ddC nor 3TC had any effect on thymidine or dCyd metabolism in either perfused heart or in isolated mitochondria. AZT has been previously shown to inhibit thymidine phospho rylation. When d4T, 3TC or ddC were given with AZT, only ddC caused a significant further decrease in thymidine phosphorylation. Conclusions: These results indicate that with the exception of the competition between AZT and thymidine, there was little competition for phosphorylation among and between these other nucleoside reverse transcriptase inhibitors and the naturally occurring deoxynucleosides in cardiac tissue and isolated heart mitochondria.
Deoxynucleoside triphosphates (dNTPs) serve as precursors for nuclear and mitochondrial DNA replication and repair. The pyrimidines deoxycytidine triphosphate (dCTP) and thymidine triphosphate (TTP) can be synthesized in many cells from a variety of precursors via de novo or salvage pathways. However, previous work has suggested that synthesis of dCTP and TTP in tissues that undergo little DNA replication (that is, non-replicating), such as the heart, might be restricted solely to the phosphorylation of deoxycytidine (dCyd) and thymidine, respectively [1] . The salvage enzymes that initiate phosphorylation of these pyrimidines in the heart include the cytosolic deoxycytidine kinase (dCK), which phosphorylates dCyd, deoxyadenosine and deoxyguanosine, and the mitochondrial thymidine kinase-2 (TK2), which phosphorylates thymidine and dCyd [2] . In addition to phosphorylating dCyd and thymidine, these enzymes also have a role in phosphorylating a variety of deoxynucleoside analogues that function as nucleoside reverse transcriptase inhibitors (NRTIs) used in highly active antiretroviral therapy in the long-term treatment of AIDS [3, 4] . As such, these drugs as a group have been associated with mitochondrial toxicity and mitochondrial DNA depletion, particularly in non-replicating tissues such as the heart [3] [4] [5] [6] . It has generally been considered that the triphosphates of the NRTIs inhibit the mitochondrial polymerase [4, 7] ; however, 3′-azido-3′deoxythymidine (zidovudine; AZT) triphosphate does not fit this model as it Introduction is a relatively weaker, mixed inhibitor of mitochondrial polymerase compared with other NRTI triphosphates and relatively little AZT triphosphate is made, especially in non-replicating tissues [8] [9] [10] . Alternatively, we have shown that AZT is a potent inhibitor of thymidine phosphorylation [8, 9] and that the heart depends solely on thymidine phosphorylation for synthesis of TTP [1] ; thus, AZT might inhibit replication of heart mitochondrial DNA by limiting the TTP available for replication.
The aim of this study was to extend this investigation to other well-characterized pyrimidine nucleoside analogues to determine the extent to which these drugs might compete with metabolism of the naturally occurring deoxypyrimidines. The naturally occurring deoxypyrimidines include thymidine, dCyd and deoxyuridine (dUrd). The four NRTIs studied here include the thymidine analogues AZT and 2′,3′-didehydrodideoxy-thymidine (stavudine; d4T), and the dCyd analogues 2′-deoxy-3′-thiacytidine (lamivudine; 3TC) and 2′,3′-dideoxycytidine (zalcitabine; ddC). Because the efficacy of these drugs depends on their phosphorylation, the phosphorylation of these analogues has been well-studied in many types of growing cells, particularly cell lines that harbour the virus [11] [12] [13] [14] [15] . However, the toxicity of these drugs has often been noted in non-replicating tissues, such as the heart [5, 6] , in which the metabolism of these compounds and their potential competition with the physiological pathways have not been studied. It seems probable that in the absence of nuclear DNA replication, the demand for dNTPs to support only mitochondrial DNA replication will be greatly reduced, as will the expression of enzymes that synthesize dNTPs in non-replicating tissues. In this study, the effect of these compounds on the phosphorylation of [ 3 H]-thymidine and [
3 H]-dCyd were investigated in the perfused rat heart and in isolated heart mitochondria.
The results of this study showed that d4T was not a substrate for phosphorylation in the heart and that 3TC and ddC were only sparingly phosphorylated. With the exception of AZT, none of the other NRTIs had a significant effect on either phosphorylation of thymidine or dCyd. Data showed that thymidine inhibited dCyd phosphorylation and dCyd inhibited thymidine phosphorylation, but with 50% inhibitory concentration (IC 50 ) values that were probably too high to have physiological significance.
Methods

Materials
All unlabelled chemicals used in this study were obtained commercially from Sigma-Aldrich (St Louis, MO, USA). Most radioactive compounds were obtained from Moravek Biochemicals (Brea, CA, USA). Tritiated dCyd and thymidine were obtained from Perkin-Elmer Life Sciences (Waltham, MA, USA).
Rat heart perfusion
Harlan Sprague-Dawley male rats (Harlan, Indianopolis, IN, USA; weighing 250-400 g) were injected intraperitoneally with heparin in saline solution (10 mg/ml) 10-45 min prior to use. Rats were anaesthetized with 1 ml sodium pentobarbital (50 mg/ml). A lateral incision was made just inferior to the diaphragm, the chest cavity was quickly opened and the heart was removed by cutting the aorta. Hearts were immediately placed in 0.9% cold saline solution and placed on a Langendorff retrograde perfusion apparatus (Indiana University School of Medicine, South Bend, IN, USA) and perfused at 37°C at a pressure of 60 mmHg as previously described [9, 16] . Briefly, hearts were initially perfused for 10 min with nonrecirculating Krebs-Henseleit buffer that was equilibrated with 95% oxygen and 5% carbon dioxide, and contained 15 mM glucose and plasma levels of amino acids. Following this washout period, isolated hearts were perfused in recirculating Krebs-Henseleit buffer that contained, in addition to above, insulin (0.1 µM/ ml perfusion buffer), 0.1% bovine serum albumin and 1 µM levels of deoxyadenosine, deoxyguanosine, dCyd and thymidine to approximate physiological levels [17] . Appropriate labelled and unlabelled pyrimidine deoxynucleosides and/or deoxynucleoside analogues were added at varying concentrations and specific radioactivities. The lengths of perfusions were 1 or 2 h. At the end of the perfusion time, hearts were immediately freeze-clamped in liquid nitrogen into thin wafers to maintain the energy charge of the tissue.
Perfused heart and perfusate preparation for HPLC analyses
The frozen heart wafers were broken into pieces in a 4°C cold room and approximately 0.2 g pieces of heart were individually weighed and homogenized in 2 ml of 5% trichloroacetic acid with an Ultra-Turrax homogenizer (IKA ® , Wilmington, DE, USA). The homogenate was precipitated on ice for 10 min and centrifuged for 3 min at 2,000×g at 4°C. A measured amount of the supernatant was removed and neutralized by adding the aliquot to a tube containing AG11A8 resin (0.5 g/ml heart extract). Tubes containing resin and heart extract were kept on ice and vortexed until the sample pH was above 6.5, and filtered into vials for analysis by HPLC using a Waters Breeze System (Waters, Milford, MA, USA). A 0.5 ml sample was removed from both the initial and final perfusates of each recirculating perfusion buffer for analysis by HPLC. The 0.5 ml perfusate sample was added to 0.5 ml 10% trichloroacetic acid and processed as described for the heart samples above. [8, 9] . Appropriate standard deoxynucleosides and deoxynucleotides were run with each experiment and, where necessary, peaks were identified by coelution with standards. The HPLC gradient conditions were modified for separation of [ 3 H]-dCyd products as described previously [1] .
HPLC analysis of perfused heart and perfusate samples
Isolation of rat heart mitochondria
Coupled mitochondria were isolated from male Harlan Sprague-Dawley rat (Harlan) heart as previously described [18] except that differential centrifugation at 4°C was adjusted to 500×g and 10,000×g for the low-and high-speed centrifugations, which improved recovery of mitochondria. Once the mitochondria were obtained, an oxygen electrode (YSI, Yellow Springs, OH, USA) was used to determine a respiratory control ratio with glutamate and malate as substrates, as described previously [18] . Only mitochondria with a respiratory control ratio value of ≥6 were used for these experiments.
Incubation of rat heart mitochondria
The isolated mitochondria were incubated at a final concentration of 4 mg/ml at 30°C in a previously defined media with 2 mM ATP [8] . For these incubations, the media was modified to include 5 mM malate. To this media, thymidine, dCyd and other deoxynucleosides and nucleoside analogues were added at varying concentrations and radioactivities.
Detection of mitochondrial phosphorylation of deoxynucleosides and their analogues by direct precipitation in isolated mitochondria
A 0.2 ml aliquot of the incubation medium was removed at various time points during incubation, noted for each group of data and mixed with an equal volume of 10% trichloroacetic acid. This mixture was allowed to sit on ice for a minimum of 10 min and then centrifuged to precipitate the solids. A 0.35 ml aliquot of the acid-soluble supernatant was removed and neutralized with 350 mg AG11A8 resin and 0.21 ml of water. This neutralized extract was filtered and analysed by HPLC.
This method yields the total of the nucleoside and nucleotide components found in the medium and in the acid-soluble portion of the mitochondrial matrix, and does not differentiate between phosphorylation within the matrix and phosphorylation outside of the matrix. However, previous work has demonstrated that phosphorylation is a matrix event [8] .
Data treatment
Values of thymidine and dCyd phosphorylation in control perfused heart were calculated by summing the values for the mono-, di-and triphosphate forms as DPM/mg wet heart. Values of thymidine and dCyd phosphorylation in isolated control mitochondria were calculated similarly. The effects of a given treatment on thymidine or dCyd phosphorylation were calculated as the percentage of the control values and shown as the mean and standard error of the mean. The IC 50 values in isolated mitochondria were obtained via best-fit graphical analysis of the data using Sigma Plot version 10.0 (Systat Software, San Jose, CA, USA).
Results
Phosphorylation of nucleoside reverse transcriptase inhibitors in the perfused heart and isolated mitochondria
The enzymes of deoxynucleoside synthesis and salvage are not expected to be well-expressed in non-replicating tissues such as the heart; thus, the first goal of this study was to determine the extent to which the thymidine analogue d4T and the dCyd analogues 3TC and ddC are phosphorylated or broken down in the perfused heart and in isolated heart mitochondria. This will provide information on the probability that these compounds will compete with thymidine or dCyd for the enzymes of the salvage pathway and the probability of toxicity caused by the triphosphate forms. Our previous work has shown that both the perfused heart and isolated mitochondria phosphorylate AZT, but only to its monophosphate form [8, 18] . Whole-heart perfusions with 1 µM [ more difficult to observe. In 5 of the 11 hearts perfused with [ Figure 1C ). The data for both 3TC and ddC suggest that expression of dCK is low and variable, potentially accounting for the significant heart to heart variation. The heart levels of the parent peaks for each of these drugs indicated that all three readily equilibrated with the intracellular space of the heart and were not limited by transport across the plasma membrane. There was no evidence of breakdown of either 3TC or ddC in the perfused heart studies ( Figure 1B and 1C) .
In isolated mitochondria, there was no evidence of phosphorylation or breakdown for any of the three drugs, d4T, 3TC or ddC (EEM and DDL, data not shown). These data suggest that the drugs are either not transported into the matrix or are not substrates for mitochondrial TK2 or deoxyguanosine kinase. Others have reported that these drugs are not substrates for purified TK2 [19, 20] . These data confirm that 3TC and ddC phosphorylations are catalysed by the cytosolic dCK enzyme.
Effects of nucleoside analogues, deoxycytidine and deoxyuridine on thymidine phosphorylation in the perfused heart and in isolated mitochondria Previous work has shown that the perfused heart readily converts [ 3 H]-thymidine to TTP [8] . Because TK1 is not active in heart, the phosphorylation of thymidine to thymidine monophosphate must occur via mitochondrial TK2; however, purified mitochondrial TK2 is also known to phosphorylate dCyd and dUrd to their monophosphates. To elicit a basic understanding of the role of substrate competition on both transport of deoxynucleoside into the matrix and TK2 activity, the effects of unlabelled dCyd and dUrd on [ 3 H]-thymidine phosphorylation in the intact perfused heart were investigated (Figure 2 ). When 100 µM of unlabelled dCyd or dUrd was added to the perfusate, there was no significant reduction in [ 3 H]-thymidine phosphorylation ( Figure 2A) ; however, inhibition was observed if the concentrations of dCyd and dUrd were increased to 500 µM (Figure 2A) .
Previous work has shown that [ 3 H]-thymidine is converted to thymidine monophosphate, thymidine diphosphate and TTP linearly with time in isolated heart mitochondria [8] . The addition of 100 µM dCyd or dUrd significantly inhibited [ 3 H]-thymidine (1 µM) phosphorylation (P≤0.001 and P≤0.005, respectively) over a 1 h incubation. The dose-response of this inhibition is illustrated in Figure 3A (dUrd) and Figure   3B (dCyd). The concentration that gave the best fit IC 50 value ±se for [ 3 H]-thymidine phosphorylation was 98 ±13 µM for dUrd and 55 ±10 µM for dCyd. The inhibitory values for dUrd and dCyd on thymidine phosphorylation in both isolated mitochondria and the perfused heart were well above concentrations that probably exist physiologically [17] , and it is not probable that either dCyd or dUrd would have an inhibitory effect in vivo.
Previous work has shown that AZT inhibits the phosphorylation of thymidine in the perfused heart [9] . To determine if other antiviral analogues affect the phosphorylation pathway, the effects of d4T, 3TC or ddC on the phosphorylation of thymidine were investigated. The effect of a 100 µM concentration of each drug is shown in Figure 2A as a percentage of thymidine phosphorylation in the absence of any drug (control). The effect of 200 µM AZT is shown in Figure 2A for comparison. Neither 3TC nor ddC had any effect on thymidine phosphorylation during perfusion. This was expected because neither drug is an analogue of thymidine. Surprisingly, d4T appeared to significantly stimulate thymidine phosphorylation (P≤0.02). The effects of 100 µM d4T, 3TC and ddC on thymidine phosphorylation were also investigated in isolated mitochondria ( Figure 2B ). As in the perfused heart, none of the analogues except AZT appeared to have any effect on thymidine phosphorylation in isolated mitochondria.
A small amount of [ 3 H]-thymidine (5-6% per h) was broken down to thymine during perfusion as has been previously noted [9] , indicating the presence of thymidine phosphorylase. This breakdown was not altered by any of the drug treatments (GWM and EEM, data not shown). There was no breakdown of thymidine to thymine in isolated mitochondria.
Effects of nucleoside analogue combination therapy on thymidine phosphorylation in the perfused heart
NRTIs are typically given as combination therapy, often with AZT as one of the drugs. Because AZT has been shown to inhibit thymidine phosphorylation in the perfused rat heart at a mean ±se IC 50 of 24 ±4 µM [9] , it was important to establish if the addition of other NRTIs given with AZT altered the effect of AZT on thymidine phosphorylation (Figure 4) . The addition of a high concentration (100 µM) of d4T, 3TC or ddC with 24 µM AZT caused a modest reduction in thymidine phosphorylation over that observed ,123 DPM/pmol) both in the presence and in the absence (control) of the various nucleoside reverse transcriptase inhibitor combinations. Experiments were performed as described in the Methods section (n=3 for each treatment group and n=12 for control). Total phosphorylation represents thymidine mono-, di-and triphosphate. The level of thymidine phosphorylation shown for each drug treatment is expressed as a percentage of thymidine phosphorylation in the control and shown as the mean ±sem. The established 50% inhibitory concentration for 3′-azido-3′deoxythymidine (zidovudine; AZT) of total thymidine phosphorylation in the perfused heart is 24 µM and was the amount given to all hearts except for controls. ddC, zalcitabine (2′,3′-dideoxycytidine); d4T, stavudine (2′,3′-didehydrodideoxy-thymidine); 3TC, lamivudine (2′-deoxy-3′-thiacytidine). with AZT alone, but only the addition of ddC reached significance. Because the typical maximal concentrations reached in treatment for these drugs are <5 µM for 3TC and d4T, and <0.1 µM for ddC [21] , these drugs are unlikely to affect thymidine phosphorylation in the heart beyond the inhibition observed with AZT. Although d4T was shown (Figure 2A ) to stimulate thymidine phosphorylation in the perfused heart, it did not 'rescue' thymidine phosphorylation in the presence of 24 µM AZT (Figure 4) .
Effects of nucleoside analogues, thymidine and deoxyuridine on deoxycytidine phosphorylation in the perfused heart and isolated heart mitochondria Previous work showed that hearts perfused with 1 µM [ 3 H]-dCyd yielded deoxycytidine monophosphate, deoxycytidine diphosphate and dCTP as phosphorylated intermediates, and that dCyd appeared to be the only precursor capable of conversion to dCTP in the perfused heart [1] . Because [ 3 H]-dCyd can be phosphorylated by either dCK or TK2 in the perfused heart, the presence of competing substrates for either enzyme could potentially affect the rate of dCyd phosphorylation. The effects of high concentrations (100 µM) of dUrd, thymidine and the NRTIs AZT, d4T, 3TC and ddC on [ 3 H]-dCyd phosphorylation are shown in Figure 5A . None of the NRTIs affected dCyd phosphorylation, including AZT, which was a potent inhibitor of thymidine phosphorylation; however, high concentrations of thymidine and dUrd did inhibit dCyd phosphorylation. This inhibition might have arisen from thymidine/dUrd interference with dCyd phosphorylation via TK2, or perhaps by disrupting dCyd transport across the mitochondrial membrane at high concentrations.
When isolated heart mitochondria are incubated with [ 3 H]-dCyd, all three phosphorylated forms were observed and increased linearly with time (DDL and EEM, data not shown) reaching a mean ±sem level of 25.5 ±2.8 pmol/mg mitochondrial protein, a rate that was approximately half the rate of thymidine phosphorylation [8] . For comparison with the intact perfused heart, the effect of other competing deoxynucleosides and deoxynucleoside analogues on [ 3 H]-dCyd phosphorylation was investigated and the results are shown in Figure 5B . Of the compounds tested, inhibition of dCyd phosphorylation was modestly observed for 100 µM AZT and dUrd, but only thymidine ]-dCyd phosphorylation in the perfused rat heart and in isolated heart mitochondria (A) Hearts were perfused with 1 µM [ 3 H]-deoxycytidine (dCyd; approximately 4,700 DPM/pmol) in the presence (100 µM) and absence (control) of thymidine (Thy), deoxyuridine (dUrd), 3′-azido-3′deoxythymidine (zidovudine; AZT), 2′,3′-didehydrodideoxy-thymidine (stavudine; d4T), 2′,3′-dideoxycytidine (zalcitabine; ddC) and 2′-deoxy-3′-thiacytidine (lamivudine; 3TC). dCyd phosphorylation is the sum of [ inhibition reached significance (P<0.05). Dose-response curves were obtained to further test the effects of AZT, dUrd and thymidine on dCyd phosphorylation in isolated heart mitochondria ( Figure 6 ). The best fit IC 50 value ±se for the effect of thymidine on dCyd phosphorylation was 57 ±16 µM, which was similar to the IC 50 observed for the effect of dCyd on thymidine phosphorylation. However, these values of inhibition are probably too high to be physiologically meaningful. The IC 50 values for AZT and dUrd were much higher and certainly not of physiological relevance. Mitochondrial TK2 phosphorylates both thymidine and dCyd, but AZT is a meaningful inhibitor only of thymidine phosphorylation. A small amount of [ 3 H]-dCyd was broken down to dUrd (mean ±sem 9 ±3%) and uracil (mean ±sem 10 ±3%) over the course of the 1 h perfusion. This indicates that both dCyd deaminase (generating dUrd) and uridine phosphorylase (generating uracil from dUrd), are present in the rat heart. The additions of other deoxynucleosides and deoxynucleoside analogues had no effect on breakdown. There was no breakdown of [ 3 H]-dCyd noted in isolated mitochondria.
Discussion
The phosphorylation of NRTIs has generally been well-studied in growing cells, especially those that harbour HIV [11] [12] [13] [14] [15] . In these studies, the efficacy of the drug depended on the ratio of NRTI triphosphate to dNTP that could be obtained, a function that depended on the competition of the NRTI and the naturally occurring deoxynucleosides for phosphorylation. The goal of the experiments in this study was to extend these studies to tissues, such as the rat heart, in which DNA replication is reduced to a very low level and the expression of the salvage enzymes are probably significantly different from growing cells. In principle, toxicity could be caused by either high levels of NRTI triphosphate inhibiting the mitochondrial polymerase [4, 7, 22] or by NRTI competition limiting phosphorylation of the naturally occurring deoxynucleosides in tissues where the salvage pathway might be the predominant or sole mechanism of dNTP synthesis [1, 8, 9, [23] [24] [25] . The importance of the TK2 salvage pathway is further confirmed by human mutations in TK2 that are associated with decreased TTP levels and that are lethal at a young age [26] . Alternatively, toxicity could be related to other unknown events. The results of this study have suggested that there is little competition between thymidine and dCyd for phosphorylation, although both are phosphorylated by TK2. dUrd has been reported as a good substrate for purified and recombinant TK2 [19, 27] ; however, it was not phosphorylated in studies in the perfused heart [1] and the presence of high concentrations of dUrd in this study did not affect thymidine or dCyd phosphorylation, except at very high concentrations (IC 50 ±se=98 ±13 and 328 ±83 µM, respectively).
The results of this study have shown that metabolism of the thymidine analogue d4T (by phosphorylation or breakdown) was not detected in either the perfused rat heart or in isolated heart mitochondria. The phosphorylation of d4T in growing cells has been attributed to the high activity of cytosolic TK1 [28] , but there is also evidence that d4T phosphorylation was unaffected in a Raji TK1-deficient cell line compared with the control Raji cells [29] . The identity of the phosphorylation enzyme in Raji cells is not clear, but it is unlikely to be the mitochondrial TK2, as d4T is not a substrate for purified TK2 [27] and, as confirmed in this study, d4T phosphorylation was not detected in the perfused heart that expresses TK2. The data presented here also demonstrated that d4T, even at very high concentrations, had no effect on phosphorylation or breakdown of dCyd in isolated mitochondria or in the perfused heart. Surprisingly, d4T appeared to stimulate thymidine phosphorylation in the perfused heart, but not in isolated mitochondria. The mechanism of this effect is unknown. There was no difference in intracellular thymidine levels suggesting that transport across the plasma membrane is not involved. Because d4T had no effect on isolated mitochondria, it seems unlikely that the effect would be mediated at the level of matrix transport or TK2 activity. Perhaps the drug inhibits cytosolic dephosphorylation pathways resulting in higher TTP levels in the perfused heart. These data support the notion that d4T is not generally associated with cardiac toxicity in humans; however, mitochondrial toxicity has been reported in a transgenic mouse line [22] . The degree to which d4T was phosphorylated in this line was not reported [22] . This difference might be related to species differences in phosphorylation or, as has recently been reported in mammals, might be caused by differences in mitochondrial DNA replication [30] . Alternatively, d4T might be too slowly phosphorylated to detect in a 2 h perfusion, but gradually accumulates over days of treatment to reach a toxic level.
The dCyd analogues ddC and 3TC were only sparingly phosphorylated in the perfused rat heart, but were not phosphorylated in isolated heart mitochondria. These results indicate that ddC and 3TC were phosphorylated by cytosolic dCK and not mitochondrial TK2. This is in agreement with work that has shown that both of these deoxynucleoside analogues were readily phosphorylated by cytosolic dCK [20, 31] , whereas they were not substrates for purified or recombinant TK2 [19, 27] . As with d4T, neither of these analogues, even at high concentrations, affected the phosphorylation or breakdown of dCyd or thymidine. Although these data support the lack of cardiac toxicity noted for 3TC in adults, they do not support the toxicity noted for ddC in rat hearts [32] . Although it has been clearly shown in growing cells that ddC toxicity is associated with phosphorylation to the triphosphate [33] , this was not the case in a rat study [32] where the ddC toxicity was noted within 6 days of treatment and was not related to any change in mitochondrial DNA. The results presented here suggest that cardiac toxicity might be caused by ddC itself.
The failure to phosphorylate d4T, 3TC or ddC in mitochondria, as noted above, is probably because of the failure of TK2 to recognize these compounds as substrates; however, it is possible that transport into the matrix might be a limiting factor. In preliminary data using fractured mitochondria (E McKee and A Bentley, unpublished observations), phosphorylation of d4T, 3TC and ddC was not observed, confirming the failure of cardiac TK2 to phosphorylate these compounds.
In summary, these results suggest that, with the exception of competition between AZT and thymidine for TK2, there is little other competition between the naturally occurring deoxynucleosides and the NRTIs used in this study. Lastly, phosphorylation of the NRTIs used in this study is not a very robust process in the isolated perfused rat heart, a tissue with relatively low levels of DNA replication. If this is a function of the absence of DNA replication, then associated toxicities in tissues of this type might not be related to the triphosphate forms.
